Real-world experience from the TRIO network assessing outcomes in patients with chronic hepatitis C treated with elbasvir/grazoprevirin the United States.

Trial Profile

Real-world experience from the TRIO network assessing outcomes in patients with chronic hepatitis C treated with elbasvir/grazoprevirin the United States.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary)
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Oct 2017 Results (n=442) presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 Oct 2017 Results of subgroup ananlysis describing the utilization and effectiveness of Elbasvir/Grazo-previr in G1a chronic HCV patients with or without NS5A RASs in the United States presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 03 Oct 2017 According to a Merck AG media release, retrospective subgroup data from this trial will be presented at The Liver Meeting 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top